AlzeCure Pharma (Q3 Review): Clinical phase IIa study in focus - Redeye
Bildkälla: Stockfoto

AlzeCure Pharma (Q3 Review): Clinical phase IIa study in focus - Redeye

Redeye returns with an update following AlzeCure’s Q3 earnings release, which aligned with our expectations. With a reinforced cash position, AlzeCure now prepares to initiate a phase IIa study with NeuroRestore ACD865 in patients with Alzheimer’s disease in 2026. Simultaneously, the company continues its business development efforts regarding all four of its candidates.

Redeye returns with an update following AlzeCure’s Q3 earnings release, which aligned with our expectations. With a reinforced cash position, AlzeCure now prepares to initiate a phase IIa study with NeuroRestore ACD865 in patients with Alzheimer’s disease in 2026. Simultaneously, the company continues its business development efforts regarding all four of its candidates.
Börsvärldens nyhetsbrev